MetaVia Inc. — Director's Dealing 2024

Jun 8, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NeuroBo Pharmaceuticals, Inc. (NRBO)
CIK: 0001638287
Period of Report: 2024-06-07

Reporting Person: Salsbury Michael (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-06-07	Common Stock	A	5051	—	Acquired	17552	Direct

Footnotes

F1: Represents a grant of restricted stock units ("RSUs") issued to the Reporting Person under the Issuer's 2022 Equity Incentive Plan, which vests on the earlier of June 7, 2025 or the day immediately prior to the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date. In accordance with the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Policy"), the Reporting Person elected to defer receipt of the shares of common stock upon the vesting of the RSUs until the earlier of the date that is (i) immediately prior to a Change in Control (as described in the Policy), or (ii) within 60 days following the Reporting Person's retirement or other separation from service with the Issuer or death, whichever is earlier.

F2: The total number of securities beneficially owned
has been adjusted to reflect the Issuer's completion
of a 1-for-8 reverse stock split on December 20,
2023.